Authors: Heather Jones, Future Science Group
Results from a clinical trial conducted at Georgetown University Medical Center (WA, USA) have revealed that Tasigna® (nilotinib), a drug typically used for cancer treatment, is reasonably safe and well tolerated by patients with Parkinson’s disease. The study, published in JAMA Neurology, follows previous research indicating that the drug acts by allowing dopamine replenishment in the brain, and suggests nilotinib potentially halts motor and non-motor decline.
Earlier investigations into the molecular properties of nilotinib have demonstrated that a single low dose of the drug can reduce levels of a toxic protein that prevents dopamine from being released in areas of the brain that control movement. As a result, it was suggested that nilotinib could be used to slow disease progression in Parkinson’s disease or dementia with Lewy bodies.